← back to search

Steve E. Kalloger

University of British Columbia · CA
Area of research
Reproductive Medicine · Oncology
Research interest
Research interests include Ovarian cancer diagnosis and treatment, Pancreatic and Hepatic Oncology Research, Cancer Genomics and Diagnostics, and Cancer survivorship and care.
h-index
58
citations
22,965
works
290
NIH funding
primary concept
email

Recent publications

Cancer-related Fatigue and the Additive Effect of Treatment in the Context of Lymphoma: An Analysis of the Lymphoma Coalition's 2022 Global Patient Survey.
2024cited by 1position: contributordoi
Mapping the experiences of people with advanced cancer across multiple cancer types-a scoping review.
2024cited by 0position: contributordoi
Table S1 from Cancer-related Fatigue and the Additive Effect of Treatment in the Context of Lymphoma: An Analysis of the Lymphoma Coalition's 2022 Global Patient Survey
2024cited by 0position: contributordoi
TABLE 1 from Cancer-related Fatigue and the Additive Effect of Treatment in the Context of Lymphoma: An Analysis of the Lymphoma Coalition's 2022 Global Patient Survey
2024cited by 0position: contributordoi
FIGURE 1 from Cancer-related Fatigue and the Additive Effect of Treatment in the Context of Lymphoma: An Analysis of the Lymphoma Coalition's 2022 Global Patient Survey
2024cited by 0position: contributordoi
Data from Cancer-related Fatigue and the Additive Effect of Treatment in the Context of Lymphoma: An Analysis of the Lymphoma Coalition's 2022 Global Patient Survey
2024cited by 0position: contributordoi
FIGURE 3 from Cancer-related Fatigue and the Additive Effect of Treatment in the Context of Lymphoma: An Analysis of the Lymphoma Coalition's 2022 Global Patient Survey
2024cited by 0position: contributordoi
FIGURE 2 from Cancer-related Fatigue and the Additive Effect of Treatment in the Context of Lymphoma: An Analysis of the Lymphoma Coalition's 2022 Global Patient Survey
2024cited by 0position: contributordoi
Table S1 from Cancer-related Fatigue and the Additive Effect of Treatment in the Context of Lymphoma: An Analysis of the Lymphoma Coalition's 2022 Global Patient Survey
2024cited by 0position: contributordoi
Loss of ATG4B and ATG4A results in two-stage cell cycle defects in pancreatic ductal adenocarcinoma cells.
2023cited by 6position: contributordoi
Stroma vs epithelium-enhanced prognostics through histologic stratification in pancreatic ductal adenocarcinoma.
2021cited by 9position: contributordoi
Advancing the Care of Pancreatic Cancer Patients: Moving Beyond Just Tumour Tissue.
2021cited by 2position: contributordoi
Genetic testing for hereditary cancer syndromes: patient recommendations for improved risk communication.
2020cited by 25position: contributordoi
Mitochondrial DNA somatic mutation burden and heteroplasmy are associated with chronological age, smoking, and HIV infection.
2019cited by 32position: contributordoi
Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer
Nature Genetics 2016cited by 367position: middledoi
Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell– and patient-derived tumor organoids
Nature Medicine 2015cited by 746position: middledoi
Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis
Oncotarget 2015cited by 76position: middledoi
Distinct evolutionary trajectories of primary high‐grade serous ovarian cancers revealed through spatial mutational profiling
The Journal of Pathology 2013cited by 434position: middledoi
Reproducibility of histological cell type in high-grade endometrial carcinoma
Modern Pathology 2013cited by 214position: middledoi
ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas
Modern Pathology 2013cited by 133position: middledoi
The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors
Modern Pathology 2013cited by 64position: middledoi
BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma
Modern Pathology 2012cited by 186position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 13 papers (2019–2024)Lorna Warwick · Lymphoma Coalition7 papers (2024–2024)Shawn Sajkowski · Lymphoma Study Association7 papers (2024–2024)Amanda Watson · 7 papers (2024–2024)Martin Köbel · University of Calgary3 papers (2012–2013)C. Blake Gilks · Vancouver Coastal Health3 papers (2012–2013)Guangming Han · Surrey Memorial Hospital2 papers (2013–2013)Sohrab P. Shah · Columbia University Irving Medical Center2 papers (2012–2013)Jiarui Ding · Harbin Normal University2 papers (2012–2013)Leah Prentice · B.C. Women's Hospital & Health Centre2 papers (2012–2013)Jessica N. McAlpine · BC Cancer Agency2 papers (2012–2013)Janine Senz · University of British Columbia2 papers (2012–2013)David G. Huntsman · Huntsman Marine Science Centre2 papers (2012–2013)Richard A. Moore · Canada's Michael Smith Genome Sciences Centre1 papers (2013–2013)Matthew Cesari · University of Saskatchewan1 papers (2013–2013)David F. Schaeffer · Vancouver Coastal Health Research Institute1 papers (2015–2015)Ie‐Ming Shih · Johns Hopkins University1 papers (2013–2013)Philip B. Clement · University Health Network1 papers (2013–2013) · 1 papers (2013–2013) · 1 papers (2013–2013)